Evidence map›Paper›PMID 34552494›Full record

ArticleFrontiers in pharmacology2021

Xinyu Yuan, Jiao Xue, Yingxia Tan, Qingguo Yang, Ziyan Qin, Xiaodong Bao, Shengkai Li, Liangliang Pan, Ziqing Jiang, Yu Wang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Therapeutic approaches to colorectal cancerFrontiers in microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Xinyu YuanWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Jiao XueWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Yingxia TanCentral Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Qingguo YangWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Ziyan QinWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Xiaodong BaoCentral Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shengkai LiWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Liangliang PanWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Ziqing JiangWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Yu WangWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Yongliang LouWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Lei JiangCentral Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jimei DuWenzhou Key Laboratory of Sanitary Microbiology, Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou, China.
Wenzhou Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first-line treatment for colorectal cancer (CRC) is 5-fluorouracil (5-FU). However, the efficacy of this treatment is sometimes limited owing to chemoresistance as well as treatment-associated intestinal mucositis and other adverse events. Growing evidence suggests that certain phytochemicals have therapeutic and cancer-preventing properties. Further, the synergistic interactions between many such plant-derived products and chemotherapeutic drugs have been linked to improved therapeutic efficacy. Polysaccharides extracted from

Indexed as

5-fluorouracilcolorectal cancergut microbiotapolysaccharideshort-chain fatty acidsβ-catenin

Identifiers

PMID34552494
PMCPMC8450769
OpenAlexW3197772149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.